Back to INEXION
Investor Overview
Seed Stage · Family Offices & Super Angels · MSO + Data Platform

The compounding
opportunity in longevity's
data gap.

INEXION is building the infrastructure layer that longevity medicine doesn't have — an MSO platform that owns anchor clinics and partners with medical associations to build a data registry no incumbent can replicate.

Request the Investor Brief See the Model
$128B+
TAM — U.S. longevity & regenerative care market
~5,000
Independent longevity clinics in the US with no unified platform
$500M+
Long-term valuation target — $500M to $1B as the platform reaches scale
The Opportunity

A massive, fragmented market
with no unified infrastructure.

Thousands of independent cash-pay longevity clinics serve high-income patients with biologics, hormone optimization, metabolic interventions, and biomarker-driven protocols — without any shared infrastructure, unified brand, or mechanism to aggregate outcomes data.

These clinics are highly profitable individually but operationally fragmented. Physicians spend enormous time on HR, compliance, billing, and administration — time taken from patients and from the science of longevity. No platform has addressed this at scale.

INEXION builds the registry from both sides: owned anchor clinics that validate data capture protocols and generate revenue from Day 1, and partnerships with medical associations (A4M, Longevity Docs) that bring hundreds of practices into the network without acquisition. Cash-pay longevity patients generate zero claims data — making this population structurally invisible to every incumbent data platform. The moat is absolute.

$128B+
TAM — U.S. longevity & regenerative care
$27B+
SAM — Independent cash-pay longevity clinic market
~5K
Independent longevity clinics in the US — no shared infrastructure
Revenue Architecture

Four interlocking
revenue streams.

INEXION is not a single-revenue-line business. The MSO model generates layered, compounding revenue — each stream reinforcing the others and growing with clinic count.

01
MSO Management Fees
Each acquired clinic pays INEXION an ongoing management fee — a percentage of clinic revenue — in exchange for the full operational stack: HR, IT, finance, compliance, and marketing. Contractually embedded, growing with clinic performance, and scaling with portfolio count.
Revenue characteristics
Contractual Recurring Scales with portfolio
02
Patient Subscriptions
A membership model introduced across all clinic locations transforms patient relationships from episodic visits to monthly recurring revenue. Subscribers receive priority scheduling, biomarker tracking, and longitudinal monitoring — converting clinic economics from lumpy to stable and investor-attractive.
Revenue characteristics
SaaS-like High retention Per-clinic
03
Data Licensing Fees
As the registry matures, INEXION's de-identified longitudinal dataset becomes a standalone commercial asset. Pharmaceutical companies, biotech firms, and research institutions pay for access to real-world longevity data — protocol performance, biomarker trajectories, treatment outcomes — that doesn't exist anywhere else. Licensing is a high-margin, non-dilutive revenue stream that scales with registry depth, not headcount.
Revenue characteristics
High-margin Non-dilutive Scales with registry
04
Real World Evidence & Clinical Trials
The INEXION registry is purpose-built for clinical research. Pharmaceutical and biotech sponsors pay to run observational studies and interventional trials through the network — accessing a pre-consented, longitudinally tracked patient population at the intersection of aging biology and preventive medicine. Site fees, patient enrollment fees, and data contribution fees create a durable research revenue stream as the registry reaches publication-grade depth.
Revenue characteristics
Sponsor-funded High-value Network-effect
The Data Asset

Every clinic added makes
the registry more valuable.

INEXION builds the registry from both sides. Owned anchor clinics generate the highest-quality longitudinal data from controlled clinical workflows. Partnerships with medical associations — like A4M and its 26,000+ member practitioners — bring hundreds of external practices into the network without acquisition. Each path reinforces the other: owned clinics prove data quality; the association network proves scale. At maturity, the data platform becomes the primary asset — publishable, licensable, and the foundation for clinical research partnerships and protocol intelligence tools. Cash-pay longevity patients are structurally invisible to every claims-based platform. No incumbent can replicate this dataset.

6K+
Patient-Years · Seed · Clinic A
First acquisition establishes the registry baseline and operational proof of concept. External clinic participation begins immediately. Subscription and biologics revenue models are introduced and validated.
40K+
Patient-Years · Series A Trigger
3–5 clinic portfolio. Registry activation at meaningful scale. Cross-site outcomes analysis becomes possible. Series A raise triggered by registry depth and recurring revenue milestones.
300K+
Patient-Years · Scale · 50+ Clinics
50+ clinics owned and external. Registry becomes publishable, licensable, and the foundation for clinical research partnerships. Platform valuation decouples from clinic count and compounds independently.
Market Timing

Why this.
Why now.

The conditions that make INEXION possible — and urgent — have converged in the last 24 months.

01
The first-mover advantage in longevity data is unclaimed
Longevity clinics are generating outcomes data right now — and almost none of it is being captured in structured, multi-site form. In five years, someone will have built this registry. INEXION is positioned to be that someone.
02
Longevity has gone mainstream
Consumer demand is outpacing clinic supply. The market is pulling clinics to scale at a pace operators can't match alone. INEXION enters a demand-led market, not a supply-push one.
03
The regulatory environment is reshaping the market
The FDA's crackdown on compounded GLP-1s has wiped out a major revenue stream for independent longevity clinics overnight. Peptides that clinics have built protocols around — BPC-157, TB-500, and others — are under active regulatory review. Solo operators have no compliance infrastructure to navigate what's coming. A unified platform does.
04
The MSO compliance window is open — briefly
Corporate Practice of Medicine laws prohibit non-physicians from owning or controlling medical practices — and enforcement is tightening fast. An MSO structure engineered for this environment separates management services from clinical control in a way that is legally defensible and operationally powerful. INEXION is building that structure now, before regulators close the grey area that late movers will depend on. The platform that gets the compliance architecture right first doesn't just avoid liability — it becomes the only credible acquirer in the market.
Capital Strategy

Designed to compound.
Not to exit on a schedule.

We are raising from the right investors — not the most capital. INEXION is a seed-stage company in active conversations with family offices and super angels who understand the healthcare services space.

We are deliberately avoiding venture capital at the seed stage. VC introduces exit pressure and quarterly performance anxiety incompatible with building a multi-decade compounding platform. The right capital comes from investors with long time horizons and genuine conviction about the longevity economy.

The seed round funds the first clinic acquisition, technology infrastructure, and initial registry architecture — minimally dilutive by design. At 3–5 clinics and 40,000+ patient-years of registry depth, we trigger a Series A on demonstrated recurring revenue and a validated data asset.

The long-term valuation target is $500M–$1B, driven by clinic EBITDA, subscription revenue multiples, and the independent value of the data platform — which at scale will attract licensing deals, research partnerships, and potentially a strategic acquirer.

Family Offices Super Angels Minimal Dilution Seed Stage No VC Pressure $500M–$1B Target
Milestone Roadmap
Seed
First Acquisition
Clinic A closes. Registry baseline established. Subscription model introduced. Operational proof of concept validated.
Year 1–2
Portfolio Build
3–5 clinics acquired. Cross-site data analysis unlocked. Recurring revenue milestones hit. Series A preparation begins.
Series A
Registry Activation
40K+ patient-years of data. Institutional capital raised. External clinic participation accelerates registry growth beyond owned portfolio.
Scale
Platform Maturity
50+ clinics. 300K+ patient-years. Registry publishable and licensable. Data platform becomes the primary valuation driver.
Leadership

Operator-built. Clinically grounded. Ready to scale.

Ian Wendt
Ian Wendt
Founder & CEO
Three decades of biopharma commercial leadership. Most recently CCO at Jaguar Health. Deep expertise in launch strategy, market access, and business development. Co-host of The RealPharma Podcast. MBA, Dalhousie University.
Na-Ri Oh
Na-Ri Oh, MD
Co-Founder & COO
Physician and global biopharma executive. MD, Heidelberg University (Studienstiftung Scholar, top 0.5%). Leadership at Boehringer Ingelheim and Gilead. Investor at Black Canyon Ventures. VC Fellow, Material Change Institute.
Nirav Vira
Nirav Vira
Chief Technology Officer
25+ years in healthcare data and AI-powered SaaS. Built a 50M-patient data lake at Verana Health. CTO of WithMe Health. Built the enterprise analytics infrastructure at Change Healthcare. B.E., University of Mumbai.
Joel Rabasco
Joel Rabasco
VP Operations
Seasoned healthcare operator. COO of ResiHealth, GM North America at Dreem Health, Head of Papa Health, CPO of BOYDSense. Enterprise experience at Qualcomm Life and Dell. MS International Management, UC San Diego.
For Investors
Request the investor brief.
We're working with a select group of family offices and super angels. If you have a long time horizon and genuine conviction about the longevity economy, we'd like to have a conversation.
Request the Investor Brief View Physician Overview